Bruning v. Hirose’s Empirical Analysis
161 F.3d 681 · 1998
Citation profile
12 federal appellate · 7 district ·
How this case has been cited
Cited by 34 later decisions — most recently January 2017 · most notably Amgen Inc. v. Hoechst Marion Roussel, Inc. (2003), Process Control Corporation v. V. Hydreclaim Corporation, Defendant-Cross (1999)
12 federal appellate · 7 district ·
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Applies 35 U.S.C. § 112 · 35 U.S.C. § 120 · 35 U.S.C. § 251 · 35 U.S.C. § 282 · 35 U.S.C. § 304 (§ 1 of the Bayh-Dole Act of 1980) · 35 U.S.C. § 305 (§ 1 of the Bayh-Dole Act of 1980)
Relies on Hybritech Inc. v. Monoclonal Antibodies, Inc. · Price v. Symsek · Genentech, Inc. v. Novo Nordisk, A/S · Monarch Knitting Machinery Corp. v. Sulzer Morat GmbH · Chemcast Corporation v. Arco Industries Corporation
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 34 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“During an interference involving a patent issued from an application that was copending with the interfering application, the appropriate standard of proof for validity challenges is the preponderance of the evidence standard.”
1 later decision quote this exact passage · from the majority“how to make and use the full scope of the claimed invention without undue experimentation.”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.